The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson’s disease with diabetes co-morbidity
ObjectiveTo investigate the effects of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide on motor function, necroptosis, and neuroinflammation in the brain in mice with diabetic Parkinson’s disease (PD) and its possible mechanism.MethodsWe prepared a diabetic model with streptozotocin...
Saved in:
| Main Authors: | Xiaomin Zhang, Pengyang Du, Bo Bai, Peng Feng, Xia Lian, Christian Hölscher, Yongqing Wang, Guofang Xue |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2025.1596506/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The interplay between α-synuclein aggregation and necroptosis in Parkinson’s disease: a spatiotemporal perspective
by: Haoran Xiang, et al.
Published: (2025-04-01) -
THSG counteracts microglial glycolytic reprogramming and neuronal necroptosis both in vivo and in vitro under conditions of neuroinflammation
by: Zhe Guo, et al.
Published: (2025-07-01) -
Exposure to BDE-209 triggers necroptosis by activating the JAK2/STAT3 signaling pathway, thereby exacerbating neuroinflammation
by: Jing Yang, et al.
Published: (2025-09-01) -
Identification of nitric oxide-mediated necroptosis as the predominant death route in Parkinson’s disease
by: Ting Zhang, et al.
Published: (2024-10-01) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)